Titlebook: Management of Castration Resistant Prostate Cancer; Fred Saad,Mario A. Eisenberger Book 2014 Springer Science+Business Media New York 2014

主講人

CHAFE

Approaches Targeting Androgen Synthesis (CYP 17 Inhibitors)econdary hormonal manipulation in castration resistant prostate cancer. Abiraterone acetate, the first in class of these therapies to receive multi-national regulatory approval and widespread clinical use, has become a new standard of care in patients with prior docetaxel chemotherapy as well as for

Boycott

詞匯表

Arroyo

Bone-Targeted Therapy: Rationale and Current Statusc fracture, the requirement of surgery or radiation to bone or spinal cord compression. SREs are associated with pain, loss of function, and decreased survival. Therefore, preventing SREs is a key consideration in the treatment of mCRPC. Osteoclast-targeted agents such as the bisphosphonate zoledron

jumble

種子

徹底明白

Phase I–II Targeted Treatmentsd further potential therapeutic targets. Optimizing the clinical development of novel anticancer drugs therefore remains an urgent priority in CRPC. In this chapter we will review issues specific to conducting Phase I and II clinical trials of targeted therapies for men with CRPC, including: trial d

沒收

Defining Clinical Endpoints in Castration-Resistant Prostate Cancerhe ability to improve overall survival (OS). The introduction of these novel compounds in our treatment armamentarium will likely challenge future drug development and registration strategies for new agents undergoing clinical testing in this patient population. The utility of endpoints including pr

fodlder

Angiogenesis Inhibition in Castration-Resistant Prostate Cancerin oncology. The pathophysiology of neovascularization has been well described in prostate cancer as well as other tumors. Identification and characterization of numerous biochemical pathways contributing to angiogenesis in cancer have allowed for the development of anti-angiogenic drugs. The applic